Patient/caregiver was instructed upon therapeutic uses and mechanism of action of Requip as follows:

  1. Low levels of the neurotransmitter dopamine and consequent reduced stimulation of dopaminergic receptors in the brain and nervous tissues, result in development of symptoms of Parkinson’s disease.
  2. Requip belongs to a class of medications called dopamine agonists, which act in place of dopamine at the dopaminergic receptors.
  3. Requip potentiates/increases the stimulation of dopaminergic receptors in the brain and nervous tissues.
  4. Potentiation of dopaminergic receptors in the nervous tissues by Requip intake contributes to relief and management of symptoms of Parkinson’s disease.
  5. Requip, by potentiating dopaminergic action can also help with management of symptoms of restless leg syndrome.